Form 4: Eli Lilly Director Defers Cash for LLY Stock

Eli Lilly director Mary Lynne Hedley acquired 13.254 shares of common stock by deferring cash compensation, increasing her direct beneficial ownership to 2,003.492 shares.

Summary

• Mary Lynne Hedley, a Director at Eli Lilly & Co (LLY), acquired 13.254 shares of common stock.
• The acquisition occurred on September 15, 2025, at a price of $748.19 per share.
• These shares were acquired by deferring cash compensation under the Lilly Directors' Deferral Plan.
• The shares will be settled in common stock following her separation from service.
• Following this transaction, Mary Lynne Hedley directly beneficially owns 2,003.492 shares of Eli Lilly & Co common stock.
• Additionally, 98 shares are indirectly beneficially owned by a Trust.

Sentiment

Score: 6

Explanation: The acquisition of shares through deferred compensation by a director is a positive signal of alignment with shareholder interests, though it is a routine compensation event rather than a discretionary open-market purchase.

Positives

• Director Mary Lynne Hedley increased her direct beneficial ownership in Eli Lilly & Co by acquiring 13.254 shares, signaling continued confidence in the company's future.
• The acquisition through deferred compensation aligns the director's long-term interests with those of shareholders.

Negatives

• No negative aspects were identified in this filing.

Risks

• No specific risks were mentioned in this filing.

Future Outlook

The shares acquired through deferred compensation will be settled in common stock following the reporting person's separation from service, indicating a long-term holding strategy.

Management Comments

• No direct quotes from management were provided in this filing; however, the action reflects the director's decision to defer cash compensation for equity.

Industry Context

This transaction represents a routine director compensation event, where equity is used to align the interests of board members with long-term shareholder value, a common practice across the pharmaceutical and broader corporate sectors.

Comparison to Industry Standards

• This type of equity-based compensation, where directors defer cash for stock units, is a standard practice in corporate governance across major U.S. public companies, including peers in the pharmaceutical industry like Johnson & Johnson or Pfizer, to foster long-term alignment and commitment.

Corporate Governance

Related Party Transactions

• Acquisition of 13.254 shares of common stock by Director Mary Lynne Hedley through the Lilly Directors' Deferral Plan, in lieu of cash compensation.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with long-term shareholder value.
• Management: Reinforces a compensation structure that encourages long-term commitment from board members.

Next Steps

• Settlement of acquired stock units in common stock following the reporting person's separation from service.

Key Dates

Keywords

Eli Lilly, LLY, Form 4, Insider Transaction, Director Compensation, Stock Acquisition, Beneficial Ownership, Pharmaceuticals